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Pilot Project Funding Opportunities 
 
November 8, 2011 
 
Gary B. Schneider, PhD 
Associate Vice Provost for Research 
Director, Office of Research Integration 
UMCCTS 
Pilot & Collaborative  
Translational & Clinical Studies 
Programs 
•  Pilot Project Program (PPP) 
•  Life Science Moment Fund (LSMF) 
Pilot Project Program 
Specific Aims: 
1.  Stimulate the development of new clinical and translational 
inter- and multi-disciplinary teams 
2.  Provide novel support mechanisms for junior investigators 
3.  Increase the emphasis on pilot funding for community-based 
research 
4.  Develop new methodologies to leverage institutional strengths 
and new initiatives 
5.  Pursue high-risk, high reward studies 
6.  Support projects utilizing the unique core facilities at the 
medical school and throughout the University 
7.  Encourage collaboration across the five UMass campuses 
Individual Proposals  $100,000 maximum for 
     1year 
    $150,000 maximum for 
     2 years 
A minimum of 2 community-based projects 
2 Stages 
Letter of Intent (2 pages) 
Full Proposal (Abbreviated NIH-style 10 pages) 
Pilot Project Program 
Pilot Project Program 
2008 Solicitation 
• 31 LOI’s submitted 
• 10 Finalists selected 
• 5 Proposals funded 
2007 Solicitation 
• 34 LOI’s submitted 
• 11 Finalists selected 
• 5 Proposals funded 
2009 Solicitation 
• 40 LOI’s submitted 
• 12 Finalists selected 
• 5 Proposals funded 
2010 Solicitation 
• 30 LOI’s submitted 
• 15 Finalists selected 
• 5 Proposals funded 
PPP Outcomes (2007-2009) 
Grants Received 15 
Presentations/Abstracts 41 
Publications 15 




UMass Life Sciences Moment Fund 
Funds dedicated to multi-investigator pilot projects identified as 
key strategy to incentivize collaborative partnerships across 
campuses. 
•  Inter-campus collaborative projects, involving at least one faculty 
member from the Worcester campus & one faculty member from 
another UMass campus. 
•  Collaborative projects must be oriented towards clinical and 
translational research. 
•  Funding levels and application review process same as PPP. 
UMass Life Sciences Moment Fund 
2009 1st Solicitation 
• 24 LOI’s submitted 
• 11 Finalists selected 
• 5 Proposal funded 
2010 Solicitation 
• 24 LOI’s submitted 
• 7 Finalists selected 
• 5 Proposals funded 
2009 2nd  Solicitation 
• 17 LOI’s submitted 
• 7 Finalists selected 
• 3 Proposals funded 
Pilot Project Program (PPP) 
Tentative Timeline: 
Request for Letters of Intent Monday, December 12, 2011 
Letters of Intent Due Friday, January 13, 2012 
Finalists Notified Friday, February 3, 2012 
Full Proposals Due Friday, March 2, 2012 
Project Start Date Monday, April 2, 2012 
Life Sciences Moment Fund (LSMF) 
Tentative Timeline: 
Request for Letters of Intent Monday, February 13, 2012 
Letters of Intent Due Friday, March 16, 2012 
Finalists Notified Friday, April 6, 2012 
Full Proposals Due Friday, May 4, 2012 
Project Start Date Monday, July 2, 2012 
Capacity	  Building	  at	  GoKids	  Boston:	  	  
An	  Inter-­‐Campus	  Ini:a:ve	  
CCTS	  seminar	  on	  pilot	  grants	  
Olga	  T.	  Hardy,	  M.D.	  
University	  of	  Massachuse;s	  Medical	  School	  
Division	  of	  Pediatric	  Endocrinology	  and	  Diabetes	  
November	  8,	  2011	  
GoKids	  Boston	  
InnovaJve	  youth	  ﬁtness,	  research	  and	  training	  
center	  on	  the	  U	  Mass	  Boston	  campus	  
Activity Frequency Time Interval
Weeks 1-5 (school year)
Exercise education 2 X / week 15 minutes
Nutrition 2 X / week 30 minutes
Exercise 2 X / week 45 minutes
Weeks 6-13 (summer break)
Exercise education 2 X / week 30 minutes
Nutrition 2 X / week 30 minutes
Exercise 4 X / week 60 minutes
13 Week Intervention
Capacity	  Building	  at	  GoKids	  Boston:	  
An	  Inter-­‐Campus	  IniJaJve	  $150,000	  
CCTS:	  Life	  Science	  Moment	  Fund	  
October	  2009	  –	  October	  2011	  
•  Fit2Lead	  pilot	  study	  -­‐	  13-­‐week	  ﬁtness	  and	  leadership	  training	  
program	  designed	  to	  promote	  academic	  achievement,	  
encourage	  ﬁtness,	  improve	  self-­‐concept	  and	  provide	  work	  
experience.	  	  
•  Recruited	  students	  at	  academic	  risk	  due	  to	  behavioral	  issues	  
or	  poor	  performance	  on	  the	  Massachuse;s	  Comprehensive	  
Assessment	  System	  test	  (MCAS).	  	  
MulJdisciplinary	  Research	  Team	  
•  Dr.	  Jean	  Wiecha	  is	  Director	  of	  GoKids	  Boston,	  and	  Associate	  
Professor	  in	  the	  Department	  of	  Exercise	  and	  Health	  Science	  
at	  the	  UMass,	  Boston.	  	  She	  combines	  experJse	  in	  nutriJon	  
science	  with	  experience	  in	  academe,	  government	  and	  
community	  based	  organizaJons.	  	  	  	  
•  Dr.	  Laura	  Hayman	  serves	  as	  the	  Research	  Director	  at	  GoKids	  
Boston	  and	  is	  Associate	  Dean	  for	  Research	  and	  Professor	  of	  
Nursing	  in	  the	  College	  of	  Nursing	  and	  Health	  Sciences	  at	  U	  
Mass	  Boston.	  Dr.	  Hayman's	  program	  and	  research	  and	  
scholarship	  focuses	  on	  primary	  prevenJon	  of	  obesity	  and	  
cardiovascular	  disease	  (CVD)	  in	  children,	  adolescents	  and	  
families.	  	  	  
•  Dr.	  Olga	  T.	  Hardy	  is	  a	  pediatric	  endocrinologist	  and	  research	  
fellow	  in	  Molecular	  Medicine	  at	  UMass,	  Worcester.	  	  She	  
provides	  experJse	  in	  metabolic	  diseases,	  and	  serum	  
biomarkers	  to	  idenJfy	  youth	  at	  risk	  for	  disease.	  
Survey	  Instruments	  and	  Data	  CollecJon	  
•  Self-­‐eﬃcacy,	  pubertal	  staging,	  
physical	  acJvity,	  dietary	  intake	  
•  Height,	  weight,	  BMI,	  waist	  
circumference,	  body	  fat	  analysis	  





•  Wiecha	  J.	  Helping	  Girls	  Work	  Toward	  Healthy	  Weights	  
at	  GoKids	  Boston.	  Panelist	  and	  presentaJon.	  U	  Mass	  
Boston	  Women's	  Research	  Forum.	  	  Boston,	  MA,	  
October	  26,	  2011.	  
•  GoKids	  Boston:	  InnovaJve	  Ideas	  for	  Fostering	  
Children's	  Health	  in	  Community	  Programs.	  	  
Workshop.	  	  Healthy	  Behaviors	  Conference,	  San	  Diego	  
CA,	  December	  2011.	  	  
.	  
•  Hayman,	  LL.	  	  PrevenJon	  of	  Obesity.	  	  PresentaJon	  at	  
the	  European	  Society	  of	  Cardiology,	  Paris,	  France,	  
August	  	  29,	  2011	  
•  Hayman,	  L.L.	  Childhood	  Obesity	  &	  Cardiovascular	  
Disease:	  Evidence-­‐based	  &	  Emerging	  Approaches	  to	  
PrevenJon	  &	  Management,	  Delaware	  Health	  
Sciences	  Alliance,	  Newark,	  Delaware,	  November	  4,	  
2011.	  	  	  
Scholarship!!	  
•  Hardy,	  O.	  T.,	  Wiecha,	  J.,	  Kim,	  A.,	  Salas,	  C.,	  Briceno,	  R.,	  
Moody,	  K.,	  Becker,	  J.,	  Glazer,	  G.,	  Ciccarelli,	  C.,	  Shi,	  L.	  
and	  Hayman,	  L.	  Eﬀects	  of	  a	  mulJcomponent	  wellness	  
intervenJon	  on	  dyslipidemia	  and	  exercise	  in	  an	  
overweight	  adolescent	  populaJon.	  	  Journal	  of	  
Pediatric	  Endocrinology	  and	  Metabolism.	  (in	  press).	  	  
	  
•  Hardy,	  O.	  T,	  Kim,	  A.,	  Becker,	  J.,	  Glazer,	  G.,	  Ciccarelli,	  
C.,	  Huston,	  B.,	  Hayman,	  L	  and	  Wiecha,	  J.	  Eﬀect	  of	  a	  
mulJcomponent	  wellness	  intervenJon	  on	  
dyslipidemia	  in	  an	  overweight	  adolescent	  populaJon.	  
Poster	  presentaJon	  at	  American	  Diabetes	  AssociaJon	  
annual	  meeJng,	  San	  Diego,	  CA,	  June	  24-­‐	  28,	  2011.	  
Pre-intervention Post-intervention Pre-intervention Post-intervention
Female, No. (%) 7 (78) 6 (67)
Ethnic group, No. (%)
  African American 9 (100) 8 (89)
  Hispanic 0 1 (11)
Age (yr) 16.3 ± 1.1 16 ± 0.7
Tanner stage, No. (%)
  3 1 (11) 2 (22)
  4 2 (22) 2 (22)
  5 6 (67) 5 (56)
BMI (kg/m2) 30.2 ± 4.4* 31 ± 4.5^^ 21 ± 1.9 21 ± 2.4
BMI % 93.6 ± 4.9* 94.8 ± 3.7^ 51.6 ± 21.3 51.4 ± 25.8
% Body fat 34.8 ± 6.4* 36.5 ± 7.3^ 21.2 ± 5.9 23.6 ± 5.6
Cholesterol (mg/dL) 138 ± 23 152 ± 33^ 136 ± 27 156 ± 37
Triglyceride (mg/dL) 51 ± 27 60 ± 34^ 48 ± 9 56 ± 25
HDL (mg/dL) 47 ± 8 54 ± 5^^ 53 ± 14 56 ± 15
LDL (mg/dL) 79 ± 24 86 ± 30 74 ± 21 93 ± 39
Systolic BP (mm Hg) 115 ± 9 121 ± 11^ 109 ± 8 112 ± 8
Diastolic BP (mm Hg) 74 ± 8 72 ± 5 74 ± 8 73 ± 4
Number of days per week 
engaged in vigorous 
physical activity
1.8 ± 2 3 ± 1.6 3 ± 1.7 3.7 ± 1.7
* P < 0.05 compared with lean group at baseline
 ^P < 0.05 within group, compared with pre-intervention testing
^  ^P < 0.01 within group, compared with pre-intervention testing
Overweight/Obese (n=9) Lean (n=9)
TABLE. Baseline and post-intervention changes in body composition, cardiovascular parameters and 
questionnaire responses 
ParJcipaJon	  i 	  Fit2Lead	  increased	  HDL	  
levels	  in	  overweight	  parJcipants	  
Scholarship!!	  
•  Increased	  Toll-­‐Like	  Receptor	  (TLR)	  AcJvaJon	  in	  
Adolescents	  with	  Metabolic	  Syndrome.	  Hardy	  OT,	  Kim	  
A,	  Ciccarelli	  C,	  Hayman	  LL,	  Wiecha	  J.	  (in	  preparaJon)	  
	  
•  Pilot	  data	  for	  grant	  applicaJons	  
•  NIH	  R21	  –	  Exploratory/Developmental	  Clinical	  
Research	  Grants	  in	  Obesity	  
–  Innate	  Immunity	  and	  Dietary	  ComposiJon	  in	  
Adolescents	  with	  Insulin	  Resistance	  
•  Amercian	  Diabetes	  Associa:on	  -­‐	  Career	  Development	  
Award	  	  
–  Eﬀects	  of	  omega	  3	  fa;y	  acids	  on	  insulin	  resistance	  
and	  innate	  immunity	  in	  youth	  
Childhood	  obesity	  is	  an	  epidemic	  
Prevalence	  of	  obesity	  among	  children	  and	  adolescents,	  by	  age	  group	  -­‐-­‐-­‐	  United	  States,	  1963-­‐2008	  
“CDC	  Grand	  Rounds:	  Childhood	  Obesity	  in	  the	  United	  States.”	  MMWR:	  Morbidity	  and	  Mortality	  Weekly	  Report.	  January	  21	  
2011.	  60(2):42-­‐46.	  	  	  
Wang Y, et al. Will all Americans become overweight or obese? estimating the progression and cost 
of the US obesity epidemic. Obesity. 2008. 
Based	  on	  current	  trends	  86%	  of	  U.S.	  adults	  will	  
be	  overweight	  by	  2030	  
www.doctorsweightsolutions.com; www.cdc.gov  
Obesity	  is	  a	  risk	  factor	  for	  numerous	  medical	  
condi:ons	  
       No 
However	  …	  not	  all	  obese	  individuals	  develop	  
complica:ons	  
51% of overweight 
adults 
31% of obese 
adults 
Metabolically healthy 
Wildman, et al. The	  Obese	  Without	  Cardiometabolic	  Risk	  Factor	  Clustering	  and	  the	  Normal	  
Weight	  With	  Cardiometabolic	  Risk	  Factor	  Clustering,	  Arch	  Int	  Med,	  Aug	  2008.	  










Mononuclear	  cells	  from	  obese	  adults	  
have	  increased	  NFκB	  binding	  and	  
increased	  expression	  of	  IL6	  and	  Tnfα	  
Mice	  lacking	  TLR2	  or	  TLR4	  are	  
protected	  from	  high	  fat	  diet	  
induced	  insulin	  resistance	  
Mononuclear	  cells	  from	  adults	  with	  
T1DM	  and	  T2DM	  have	  increased	  
expression	  of	  TLR2,	  TLR4,	  CCL2	  and	  
increased	  secreJon	  of	  IL6	  and	  Tnfα	  
Devaraj S, et al.. J Clin Endocrinol Metab. 2008; Bradshaw EM, et al. J Immunol. 2009; Cipolletta C, et al. Diabetes. 2005; Devaraj 




• Overweight	  with	  metabolic	  syndrome	  	  
	   	  (Overwt-­‐MetSyn)	  
• Overweight	  without	  metabolic	  syndrome	  	  
	   	  (Overwt-­‐Healthy)	  
•  Lean	  
2	  
Assess	  inﬂammatory	  state	  
Gene	  expression	  
•  Toll-­‐like	  receptors	  (TLR2,	  TLR4)	  
•  Cytokines	  (Tnfα,	  IL6)	  
Correlate	  monocyte	  inﬂammaJon	  
with	  anthropometric	  measurements	  
and	  serum	  markers	   	   	   	   	  	  
• BMI,	  Waist	  circumference	  




1.  Monocytes	  from	  Overwt-­‐MetSyn	  subjects	  will	  have	  increased	  
gene	  expression	  of	  TLRs	  and	  cytokines	  when	  compared	  to	  
Overwt-­‐Healthy	  and	  Lean	  subjects	  
2.  TLR	  and	  cytokine	  expression	  will	  show	  a	  posiJve	  correlaJon	  with	  
anthropometric	  and	  serum	  markers	  of	  metabolic	  disease	  
1	  
TABLE. Anthropometric and laboratory data of study participants
Overwt MetSyn Overwt Healthy Lean
(n=9) (n=8) (n=9)
Females/males 9/0 5/3 6/3
Age (yr) 16.4 ± 0.4 16.8 ± 0.4 16.5 ± 0.2
Ethnic group, No. (%)   
  African American 5 (56) 6 (76) 6 (67)
  Caucasian 1 (11) 1 (12) 1 (11)
  Hispanic 3 (33) 1 (12) 2 (22)
BMI (kg/m2) 37 ± 3a 31 ± 2a 21 ± 1c
BMI % 97 ± 1a 94 ± 2a 44 ± 5c
Waist circumference 111 ± 7a 95 ± 5a 74 ± 2c
Systolic BP (mm Hg) 124 ± 3a 116 ± 4 112 ± 2c
Diastolic BP (mm Hg) 75 ± 4 72 ± 3 72 ± 1
White blood cell counts (k/uL)d 8 ± 1a 6 ± 1 6 ± 0
Monocytes (%)d 9 ± 1 8 ± 1 8 ± 1
Absolute monocytes (th/mm3)d 0.6 ± 0.1a,b 0.5 ± 0 0.4 ± 0
Cholesterol (mg/dL) 146 ± 7 148 ± 11 144 ± 9
Triglyceride (mg/dL) 96 ± 9a,b 45 ± 8 59 ± 7
HDL (mg/dL) 46 ± 3 57 ± 4 53 ± 4
LDL (mg/dL) 81 ± 6 83 ± 8 79 ± 7
Fasting glucose (mg/dL)d 97 ± 5 91 ± 5 94 ± 3
TNFa  (pg/mL) 1.8 ± 0.6a,b 0.4 ± 0.1 0.8 ± 0.2
IL6 (pg/mL) 3 ± 1a,b 1.1 ± 0.3 0.7 ± 0.2c
Data presented as mean ± SEM
a  P < 0.05 compared with lean
b  P < 0.05 compared with overweight healthy
c P < 0.05 compared with all overweight (Overweight healthy and Metabolic syndrome)
d  Information not available in all patients
Monocytes	  from	  Lean	  and	  all	  Overweight	  
























Monocytes	  from	  Overwt-­‐MetSyn	  subjects	  display	  






























Conclusions 	  	  
Adolescents	  
•  Overwt-­‐MetSyn,	  Overwt-­‐Healthy,	  Lean	  
Yes	  
Assess	  inﬂammatory	  state	  
Gene	  expression	  
•  TLR2,	  TLR4,	  Tnfα,	  IL6	  
Correlate	  monocyte	  gene	  expression	  
with	  anthropometric	  measurements	  
and	  serum	  markers	   	   	   	   	  	  
• BMI,	  Waist	  circumference,	  Tnfα,	  IL6	  
Monocyte	  
1.  Monocytes	  from	  Overwt-­‐MetSyn	  subjects	  display	  increased	  gene	  
expression	  of	  TLRs	  and	  cytokines	  
2.  TLR	  expression	  shows	  a	  posiJve	  correlaJon	  with	  circulaJng	  
cytokines;	  cytokine	  expression	  correlates	  with	  BMI	  and	  waist	  
circumference	  
Ongoing	  research	  
1.  Recruit	  more	  subjects	  
2.  Assess	  TLR	  protein	  expression,	  surface	  markers	  
3.  Measure	  intracellular	  cytokines	  (Tnfα,	  IL6)	  from	  monocytes	  at	  
baseline	  and	  in	  response	  to	  dietary	  lipids	  
Center for Clinical and Translational Science (CCTS)  
Pilot Program Project (PPP)  
 
“New Therapeutic Strategy for the Treatment of Hard-
to-heal Bony Lesions” 
 
PI: Jie Song, PhD  
Co-I: David Ayers, MD 
 
7/1/2007-6/30/2009 
Surgical reconstruction using proper bone grafts:  
 Volumetric bone loss (trauma, tumor resection) 
 Hard-to-heal skeletal defects (diabetic, osteoporotic) 
Clinical needs for bone grafts 
Bostrom & Seigerman  
HSS J. 2005;1:9-18.  
Desired characteristics of synthetic bone grafts 
• Bone-like structural properties 
• Biochemical microenvironment facilitating osteointegration  
• Physical properties enabling stable surgical fixation 
Current Synthetic bone substitutes / grafts 
• Weak gel foams, brittle ceramics 
• Permanent metal support 
• Graft failure (inadequate fixation & osetointegration) 
Multifaceted role of nanocrystalline HA (nHA) in defining properties of bone: 
  
 - Provide mechanical strength 
 - Support bone cell attachment 
 - Serves as a reservoir for Ca2+ and PO43- ions 
 - Retain secreted factors  
~50-70%  
dry weight 
Inspiration from bone 
• High (50 wt%) osteoconductive nHA content 
• Elastomeric properties facilitating press-fitting 
• Strong integration between hydrogel and nHA 
  Resistance to brittle fractures 
  Retention and sustained release of biomolecules:  
  reduced minimal loading dose by 100-1000 fold 
FlexBone: An elastomeric hydrogel-nHA composite 
• FlexBone 
• FlexBone + rhBMP-2/7 (400 ng) 
FlexBone promoting the repair of 5-mm rat femoral defects 
Functional repair of defect by  
FlexBone+400ng rhBMP-2/7 in 8-12 weeks 
Higher BMC 
Lower BMC 
Restoration of torsional strength: Recanalized bony calluses completely  






 Filion TM et al. Tissue Eng. Part A 2011, 17, 503-511. 
FlexBone alone enabled partial repair of defects by 12 weeks 
FB = FlexBone; NB = New bone; BM = Bone marrow; * Un-mineralized callus 
External callus (EC) encapsulating the exterior of FlexBone: 





Scale bars = 200 µm 




Synergistic delivery of multiple growth factors and 
antibiotics to expedite the healing of critical-size diabetic 
bony lesion with reduced infections  
Students & fellows trained/supported by PPP 
• Graduate student: 
Tera Filion Potts 
 
• Postdoctoral fellow: 
Jianwen Xu, PhD 
 
• Orthopedic research resident: 
Xinning Li, MD 
Subsequent funding support built upon PPP 
• R01AR055615 (Song, 2008-2013) 




• R01GM088678 (Song, 2009-2013) 
“A NANOSTRUCTURED APPROACH TO COMPLEX TISSUE SCAFFOLDS AND SMART 
IMPLANTS”  
 (NIH/NIGMS; EUREKA project) 
 
• Resident Clinician Scientist Training Grant (Li & Song, 2009-2010) 
“Osteoconductive Elastomeric Synthetic Bone Composite Graft for the Repair of Critical 
Sized Femoral Defects in Rats”  
 (Orthopaedic Research and Education Foundation ) 
 
Publications during PPP funding period: 
 
• Jie Song, Jianwen Xu, Tera Filion, et al. J. Biomed. Mater. Res. 2009, 89A (4), 1098-
1107.  
• Jianwen Xu, Xinning Li, Jane B. Lian, David C. Ayers and Jie Song. J. Orthop. 
Res. 2009, 27 (10), 1306-1311. 
 
 
Publications resulting from subsequent R01’s (built upon and extended from PPP): 
 
• Jianwen Xu and Jie Song. Proc. Natl. Acad. Sci. USA  2010, 107 (17), 7652-7657.  
• Tera M. Filion, Jianwen Xu, Manju L. Prasad and Jie Song. Biomaterials 2011, 32, 
985-991. 
• Tera M. Filion, Xinning Li, April Mason-Savas, et al. Tissue Eng. Part A 2011, 17 (3-
4), 503-511. 
